Chemotherapy Pneumonitis: Signs, Causes, and Treatment

Chemotherapy pneumonitis is lung inflammation triggered by cancer-fighting drugs, and it accounts for a meaningful share of treatment-related complications across oncology. The condition develops when a chemotherapy agent, immunotherapy drug, or newer antibody-drug conjugate damages the delicate tissue lining the air sacs in the lungs, provoking an inflammatory response that can range from barely noticeable to life-threatening. Drug-induced interstitial lung disease makes up roughly 3–5% of all interstitial lung disease cases seen in clinical practice, but in certain drug classes the rate climbs much higher.

What Happens in the Lungs

Your lungs exchange oxygen and carbon dioxide through millions of tiny air sacs called alveoli, separated from blood vessels by a thin membrane. Chemotherapy pneumonitis occurs when a drug or its byproducts injure the cells that form this membrane, setting off inflammation in the surrounding tissue. The body’s immune response floods the area with inflammatory cells and fluid, thickening the membrane and making gas exchange harder. In mild cases, the damage stays limited and reversible. In severe cases, the inflammation can progress to scarring (fibrosis) that permanently stiffens lung tissue.¹

The exact way a drug injures the lung varies. Some agents produce toxic metabolites that directly damage alveolar cells. Others trigger an immune-mediated reaction where the body’s own defenses attack lung tissue. Newer antibody-drug conjugates appear to work through a different route: immune cells called alveolar macrophages absorb the drug independently of its intended cancer target, release the toxic payload inside the lung, and spark a cascade of inflammatory signaling.² These varied mechanisms are one reason the condition can look so different from patient to patient.

Signs and Symptoms

The symptoms of chemotherapy pneumonitis overlap heavily with common respiratory infections, which is part of what makes it tricky to catch early. The most frequent complaints are shortness of breath, a persistent dry cough, fatigue, and low-grade fever.³ Some people describe the breathlessness as gradual, worsening over weeks, while for others it arrives abruptly. Chest tightness and a general sense of being unwell round out the picture, though none of these on their own point specifically to pneumonitis.

One underappreciated aspect is that the condition can be completely asymptomatic in some patients, found only when a routine scan reveals changes in the lungs. In others, the onset is insidious and builds slowly enough that it gets dismissed as deconditioning or anxiety. Symptoms can even appear after treatment has ended, not just during active cycles. The median time between starting the responsible drug and developing pneumonitis sits around seven to eight weeks, though the range is enormous, stretching from under two weeks to well over two years depending on the drug and the patient.³

Severity matters a great deal for what happens next. Oncologists typically grade the condition on a scale from 1 to 4. Grade 1 means imaging shows changes but you feel fine. Grade 2 means symptoms like cough and breathlessness are present and interfering with daily activities. Grades 3 and 4 involve severe respiratory distress, often requiring hospitalization and supplemental oxygen. The grading directly determines how aggressively doctors treat the pneumonitis and whether the cancer therapy continues.

Which Drugs Are Involved

Almost any category of anticancer drug has been linked to pneumonitis, but some are notorious for it. Classic cytotoxic chemotherapy agents like bleomycin have been recognized as lung-toxic for decades. The incidence of bleomycin-related lung injury depends heavily on cumulative dose, the underlying cancer, and whether the patient is also receiving radiation.⁴ Methotrexate, widely used for both cancer and autoimmune conditions, can also produce a distinctive pneumonitis pattern, though the reaction is considered infrequent.⁵

In recent years, the spotlight has shifted to newer drug classes. Immune checkpoint inhibitors, which unleash the immune system against tumors, carry a well-documented pneumonitis risk because the same immune activation that fights cancer can attack healthy lung tissue.⁶ Antibody-drug conjugates (ADCs), a fast-growing class that delivers potent toxins directly to cancer cells, have raised particular concern. Pooled data for trastuzumab deruxtecan, one of the most widely used ADCs, show an interstitial lung disease incidence of roughly 10–15%, a median onset of five to six months, and a fatal-event rate of about 2.2%.² Pulmonary toxicity with ADCs is not confined to one drug target; agents directed at TROP2, HER3, and other markers have also been implicated.

Targeted therapies such as EGFR inhibitors, ALK inhibitors, and mTOR inhibitors fill out the list. A review of pulmonary toxicities in non-small cell lung cancer found that pneumonitis arises across chemotherapy, antibody-drug conjugates, targeted therapy, and immunotherapy alike, reinforcing that no modern cancer drug class is entirely free of this risk.⁷

Risk Factors That Raise the Odds

Not everyone receiving these drugs develops lung inflammation. Several factors tilt the probability. Age, smoking history, kidney dysfunction, cumulative drug dose, concurrent radiation to the chest, and supplemental oxygen therapy have all been identified as contributors.⁸ Combining multiple lung-toxic treatments compounds the risk; a patient receiving both chemotherapy and chest radiation faces a higher probability of pneumonitis than someone receiving either alone.

The single most potent risk factor getting attention is pre-existing interstitial lung disease. A meta-analysis found that patients who already have some form of ILD face roughly four times the odds of developing any-grade pneumonitis from checkpoint inhibitors, and about three times the odds of severe pneumonitis.⁹ A smaller retrospective study put the odds ratio for pre-existing ILD even higher, around 19 in a multivariate analysis, though the wide confidence intervals reflect a small sample.¹⁰ The practical upshot is that patients with known ILD require closer monitoring from the start of treatment.

Genetic susceptibility is another emerging area of interest. Research in childhood cancer survivors suggests that both common genetic variants and rarer structural changes in the genome may help explain why some patients develop pulmonary toxicity and others do not, even when receiving identical regimens.¹¹ This line of investigation is still early, but it points toward a future in which genetic screening could flag high-risk patients before treatment begins.

How Doctors Diagnose It

There is no single blood test or imaging finding that definitively confirms chemotherapy pneumonitis. It is a diagnosis of exclusion: doctors must first rule out infection, disease progression in the lungs, fluid overload, blood clots, and other causes of respiratory symptoms before concluding that a drug caused the inflammation. That workup typically includes microbial cultures, blood tests for infection markers, and sometimes a bronchoscopy to sample fluid from the airways.

High-resolution CT scanning is the primary imaging tool. The patterns that show up on CT can look like several different types of interstitial lung disease. One retrospective study of chemotherapy-induced cases found that the most common CT pattern mimicked hypersensitivity pneumonitis, accounting for about half of cases, followed by nonspecific interstitial pneumonia, organizing pneumonia, and diffuse alveolar damage.¹² Checkpoint-inhibitor-related pneumonitis shows a somewhat different pattern distribution: organizing pneumonia tends to be the most common pattern, with ground-glass opacities being the single most frequent imaging feature.¹³

Because imaging alone cannot distinguish drug-induced lung injury from infection or tumor spread, a multidisciplinary approach matters. Pulmonologists, oncologists, and radiologists ideally review each case together. Expert consensus guidelines stress that differential diagnosis should include serological and microbial testing to confirm or exclude infectious causes before attributing lung changes to the drug.

An Emerging Blood Marker

One promising development on the diagnostic front involves a biomarker called KL-6 (Krebs von den Lungen-6), a protein shed by damaged lung cells. In patients who developed checkpoint-inhibitor pneumonitis, KL-6 levels rose sharply at onset, jumping from a pre-treatment median of about 222 U/mL to 743 U/mL. The biomarker performed well in distinguishing patients with pneumonitis from those without it, with sensitivity around 81% and specificity around 92% when using a threshold of roughly 1.5 times the patient’s own baseline value.¹⁴ The increase appeared regardless of how severe the pneumonitis was, suggesting KL-6 could be useful for catching mild cases early, not just confirming bad ones. Regular KL-6 monitoring during immunotherapy is already practiced in some Japanese oncology centers, though it has not yet become standard worldwide.

Treatment by Severity

The first and most universal step is stopping the offending drug. For many patients, that alone plus supportive care is sufficient for low-grade pneumonitis. Beyond that, corticosteroids are the backbone of treatment, with dosing escalating in step with severity.

For grade 1 disease, clinicians may hold treatment and monitor closely with repeat imaging, sometimes without starting steroids at all. Grade 2 calls for prompt drug discontinuation and steroid therapy, typically prednisone at about 1–2 mg per kilogram of body weight per day, continuing until symptoms and imaging improve, then tapered gradually over at least four to six weeks. Grade 3 pneumonitis follows a similar corticosteroid regimen but often involves intravenous methylprednisolone and hospital admission. Rapid tapering at any grade raises the risk of pneumonitis flaring back up.¹⁵

One study of treatment-related pulmonary toxicities in lung cancer patients found that about 73% of those with drug-induced lung disease received high-dose or pulse-dose steroids, compared with lower rates in radiation pneumonitis and other pulmonary complications.¹⁶ The high prescription rate reflects how central steroids are to managing this particular form of lung injury.

When Steroids Are Not Enough

A subset of patients does not respond adequately to corticosteroids, a situation called steroid-refractory pneumonitis. This is where management becomes more complex. International consensus guidelines from ESMO, ASCO, SITC, and NCCN all recommend infliximab, mycophenolate mofetil (MMF), and intravenous immunoglobulin (IVIG) as second-line options. The most recent NCCN guidelines place MMF and IVIG as preferred over infliximab for grade 3 and 4 checkpoint-inhibitor pneumonitis.¹⁷

Case reports have demonstrated that MMF can resolve pneumonitis that persists despite weeks of high-dose steroids. In documented cases, patients saw their symptoms improve, lung shadows clear on imaging, and were eventually able to discontinue both steroids and MMF without the pneumonitis returning.¹⁸ Additional agents such as cyclophosphamide and calcineurin inhibitors have shown benefit in isolated cases, and there is early interest in tocilizumab, a drug that blocks an inflammatory signaling molecule called interleukin-6, though evidence for these options remains limited.¹⁷

Restarting Cancer Treatment After Pneumonitis

One of the most consequential decisions after recovery from chemotherapy pneumonitis is whether to rechallenge the patient with the same drug, switch to a different agent, or stop treatment altogether. The default stance is caution: rechallenge with the drug that caused interstitial lung disease is generally considered contraindicated. But oncology rarely has the luxury of simple rules. When alternatives are limited and the cancer is progressing, the calculus changes.

In pancreatic cancer, where effective treatment options are particularly scarce, researchers found that rechallenge after recovery from pneumonitis was safe and actually associated with better survival compared with not resuming treatment.¹⁹ Case reports in non-small cell lung cancer have described successful reintroduction of osimertinib, an EGFR-targeted drug, even after severe, rapid-onset pneumonitis, provided that the patient’s lung findings and symptoms had fully resolved before restarting.²⁰

These decisions are highly individualized. Factors that weigh in favor of rechallenge include how severe the initial episode was, how quickly and completely the lungs recovered, whether the specific drug has unique efficacy against the patient’s tumor, and whether reasonable alternative treatments exist. In most cases, rechallenge is attempted under close surveillance with more frequent imaging than usual.

Prognosis and What Affects It

Outcomes span a wide range. Most patients with grade 1 or 2 pneumonitis recover fully, especially when the condition is caught early, the drug is stopped promptly, and steroids are started before the inflammation has time to progress. Grade 3 or higher cases carry a less favorable outlook. In the context of antibody-drug conjugates, acute respiratory distress syndrome, the most dangerous form of lung toxicity, had the earliest onset and the highest case fatality rate among pulmonary events.²

One finding with direct clinical relevance is that a short interval between starting the drug and developing pneumonitis predicted shorter survival, as did the inability to resume any anticancer therapy after the pneumonitis episode.³ In other words, the pneumonitis itself is often survivable, but the treatment interruption it forces can affect cancer outcomes. Early recognition and management become doubly important: they protect the lungs and they preserve the ability to continue fighting the underlying cancer.

Why the Condition Is Increasingly Common

If chemotherapy pneumonitis feels like it is getting more attention than it used to, that is because the landscape of cancer treatment has shifted in ways that increase exposure. Immune checkpoint inhibitors are now approved across dozens of cancer types and are being combined with chemotherapy in first-line regimens, multiplying the population at risk. Antibody-drug conjugates are one of the fastest-growing drug classes in oncology, and their unique mechanism of lung injury means that pneumonitis rates in ADC-treated patients are higher than most older chemotherapy agents ever produced. One pharmacovigilance analysis of over 1,200 ADC-related pulmonary events found that interstitial lung disease, pneumonitis, and acute respiratory distress syndrome accounted for the vast majority of lung complications, with ILD alone representing about 41% of events.²

Combination regimens also play a role. Adding chemotherapy to immunotherapy, or layering targeted agents onto either, increases the probability of lung toxicity beyond what any single agent would produce alone. As cancer medicine shifts toward multi-drug, multi-mechanism treatment strategies, the lung finds itself exposed to overlapping insults. This trend is why oncology teams are investing more effort into monitoring protocols, biomarker development, and standardized grading systems: the problem is not going away, and managing it well has become a core competency in modern cancer care.

Monitoring Strategies During Treatment

Given that early detection improves outcomes, the question of how to monitor patients during potentially lung-toxic therapy is a practical one. Baseline lung function testing and CT imaging before starting treatment provide a comparison point. During treatment, many centers rely on symptom-based monitoring: patients are educated to report new or worsening cough, breathlessness, or fever immediately, and clinicians maintain a low threshold for ordering CT scans when these symptoms appear.

For higher-risk drug classes like ADCs, some multidisciplinary teams in Asia have adopted routine interval CT scans regardless of symptoms, particularly in the first six months when onset is most likely. Blood-based monitoring with KL-6 is another layer that some centers add, especially for patients on checkpoint inhibitors. The goal across all these approaches is the same: catch the pneumonitis at grade 1 or 2, before it advances to a grade where treatment options narrow and recovery becomes uncertain. The evidence is clear that stopping the responsible drug early, before severe lung damage sets in, is the single most important step in management.⁷

1
Europe PMC. Anticancer therapy and lung injury: molecular mechanisms
2
PubMed. Interstitial lung disease in patients treated with antibody-drug conjugates: a review
3
PubMed Central. Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis
4
Europe PMC. Reversible Acute Lung Injury due to Bleomycin
5
Europe PMC / Hindawi. Methotrexate-induced pulmonary toxicity
6
PubMed Central. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
7
Europe PMC. Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer
8
Journal of Thoracic Oncology. Chemotherapy-Induced and Other Drug-Induced Lung Disease
9
PubMed Central. The impact of pre-existing interstitial lung disease on radiation and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis
10
PubMed Central. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis
11
Scientific Reports. Role of genetic modifiers on pulmonary consequences of cancer therapy in children
12
PubMed Central. Thin-Section CT Characteristics and Longitudinal CT Follow-up of Chemotherapy Induced Interstitial Pneumonitis: A Retrospective Cohort Study
13
PubMed. High-Resolution CT Patterns of Anti-PD1 Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
14
Journal for ImmunoTherapy of Cancer. Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis
15
ESMO Open. Management of drug-induced interstitial lung disease in cancer patients: a multidisciplinary expert position paper
16
PubMed Central. Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer
17
Medical Research Archives. Checkpoint Inhibitor Pneumonitis: Updates in Management
18
PubMed Central. Effective treatment of steroid-resistant immune checkpoint inhibitor pneumonitis with mycophenolate mofetil
19
PubMed Central. Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis
20
PubMed Central. Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis